Home
Forms Library
Assessment of Analgesic Treatment of Chronic Pain - fda

Assessment of Analgesic Treatment of Chronic Pain - fda 2025

Assessment of Analgesic Treatment of Chronic Pain - fda Preview on Page 1

See details

4 out of 5

46 votes

The document is a disclosure form for speakers, panelists, and moderators participating in the FDA Public Workshop on the Assessment of Analgesic Treatment of Chronic Pain. It requires participants to disclose any financial or beneficial interests related to analgesic drug products, ensuring transparency regarding potential conflicts of interest. The completed forms will be publicly posted alongside workshop materials.

Here's how it works

01. Edit your form online

Type text, add images, blackout confidential details, add comments, highlights and more.

02. Sign it in a few clicks

Draw your signature, type it, upload its image, or use your mobile device as a signature pad.

03. Share your form with others

Send it via email, link, or fax. You can also download it, export it or print it out.

How to use or fill out Assessment of Analgesic Treatment of Chronic Pain - fda with our platform

Ease of Setup

DocHub User Ratings on G2

Ease of Use

DocHub User Ratings on G2

Click ‘Get Form’ to open it in the editor.
Begin by entering your name in the designated field for 'Name of Meeting Participant'. Ensure that your name is spelled correctly as it will be publicly posted.
In the section regarding financial arrangements, list any affiliations or beneficial interests you have had in the past three years. Be specific about each company and the nature of your involvement, such as consulting or stock ownership.
If you have no conflicts of interest to report, clearly state 'no conflicts' in the appropriate field. This is crucial for transparency.
Sign the form electronically using our platform’s signature feature to validate your submission.
Once completed, email the form to Mary Gross at mary.gross@fda.hhs.gov by May 21. Make sure to double-check all entries for accuracy before sending.

Start filling out your form today for free and streamline your submission process with our editor!

be ready to get more

Complete this form in 5 minutes or less

Get form

Got questions?

We have answers to the most popular questions from our customers. If you can't find an answer to your question, please contact us.

What are the CDC guidelines for opioid prescribing?

The 2022 Centers for Disease Control and Prevention guideline reiterates that clinicians should prescribe opioids at the lowest effective dose for the expected duration of pain warranting opioid use. The guideline also endorses patient-centered approaches to the initiation or taper of opioids.

When did CDC change opioid guidelines?

The 2022 Clinical Practice Guideline includes information that updates and replaces the 2016 CDC Guideline for Prescribing Opioids for Chronic Pain.

What is the first step to take when considering prescribing an opioid for pain management in an older individual?

When considering the use of opioids for chronic pain, careful and thorough patient assessment is critical. Assessment of the patients pain and risk stratification is a key element to mitigate potentially adverse consequences of opioid prescribing and ensure proper patient monitoring.

What is the new FDA approved analgesic?

The Food and Drug Administration Jan. 30 announced it approved Journavx (suzetrigine) oral tablets, a first-in-class non-opioid drug, to treat moderate to severe acute pain in adults.

Which action is recommended by the CDC guidelines when initiating opioid therapy for chronic pain?

When initiating opioid use, clinicians should prescribe and advise opioid use only as needed. Involve patients in decisions about whether to initiate opioid use, including discussing the benefits and risks of starting or continuing opioid therapy.

What is the FDA PMR 3033 2?

3033-2 An observational study designed to measure the incidence and predictors of opioid overdose and death (OOD), as well as opioid abuse/addiction, using patient health records, insurance claims, and death records.

What does the CDC recommend when tapering opioid dosages?

A decrease of 10% of the original dose per week is a reasonable starting point. Some patients who have taken opioids for a long time might find even slower tapers (e.g., 10% per month) easier. Discuss the increased risk for overdose if patients quickly return to a previously prescribed higher dose.

What to monitor with analgesics?

Harmful effects from opioid analgesics include nausea, constipation, itchiness, drowsiness and slowed breathing. Your clinician will monitor adverse effects by regularly checking your breathing, how drowsy you are and how often you are going to the toilet.

Assessment of Analgesic Treatment of Chronic Pain - fda 2025

Here's how it works